Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Leading distributor of pharmaceuticals and medical supplies Cardinal Health (CAH - Analyst Report) recently revealed that, for the sixth straight year, it will provide grants to aid Puerto Rican, Canadian and U.S. healthcare facilities to improve the quality and efficiency of patient care. Till date, the Cardinal Health Foundation has handed out 190 grants aggregating over $5.25 million.

Applicants to the Cardinal Health Foundation E3 Grant Program are being asked to provide requests either for efforts that will enhance medication safety (especially as patients are shifted from inpatient facilities to their residence) or for endeavors that will enhance operating room precautionary measures in line with WHO guidelines.

Grant recipients engaged in medication safety efforts will be supported by specialists from the Cardinal Health Pharmacy Solutions Team. Recipients involved with surgical problems will be guided by experts from the Association of periOperative Registered Nurses (AORN).    

Prospective grant applicants may consult the AORN site for ideas regarding better practices. The Cardinal Health community site provides briefs of past proposals which were accepted.

As per concerned inpatient facilities, past grants have helped them to cut down on their mistakes. In fact, previous grant recipients have provided a return of 11 times the original investment by Cardinal Health Foundation.   

The Cardinal Health Foundation will host two web sessions on the subject on October 23 and October 26, 2012. Applicants must submit their proposals at the Cardinal Health community website by December 7, 2012.

Cardinal Health is ranked among Fortune 500 companies. With over $100 billion in annual sales, Cardinal Health remains one of the largest distributors of pharmaceuticals and medical supplies in the U.S. The company’s diversified product portfolio may partly insulate it from the current economic uncertainty.

The company stands to gain from the gradual shift in mix from bulk to the higher-margin non-bulk sector of the Pharmaceutical segment. It is also riding the generic wave. Overall, Cardinal benefits from a spate of tuck-in acquisitions and capital deployment strategies.

However, the company faces tough competition across all business segments, which may continue to pressure pricing and margins. Its major competitors in the pharmaceutical supply chain segment include McKesson Corp. (MCK - Analyst Report) and AmerisourceBergen Corp. (ABC - Analyst Report). We have a long-term Neutral recommendation on Cardinal.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%